A synthetic TLR7/8 ligand
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

R-848

Item No. 14806

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4-amino-2-(ethoxymethyl)-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol
CAS Number
144875-48-9
Synonyms
  • Resiquimod
  • S 28463
Molecular Formula
C17H22N4O2
Formula Weight
314.4
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 16 mg/mlDMF:PBS (pH 7.2) (1:1): 0.5 mg/mlDMSO: 12.5 mg/mlEthanol: 3.3 mg/ml
λmax
249, 328 nm
SMILES
NC1=NC2=CC=CC=C2C3=C1N=C(COCC)N3CC(C)(C)O
InChi Code
InChI=1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19)
InChi Key
BXNMTOQRYBFHNZ-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $54

    Add

    10 mg

    $91

    Add

    25 mg

    $185

    Add

    50 mg

    $315

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    R-848 is an immune response modifier that mimics the pathogen-associated molecular patterns that activate immune cells through Toll-like receptor 7 (TLR7) and TLR8. It demonstrates potent anti-tumor and anti-viral properties and has been used to study the innate immune response to viral infections. 1,2,3 At 1 μg/ml, R-848 mimics CD40-induced B cell activation and can be used to induce the production of IFN-γ and various other cytokines.4,5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Bernstein, D.I., Harrison, C.J., Tomai, M.A., et al. Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. J. Infect. Dis. 183(6), 844-849 (2001).

    2. Nian, H., Geng, W.Q., Cui, H.L., et al. R-848 triggers the expression of TLR7/8 and suppresses HIV replication in monocytes. BMC Infect. Dis. 12, 5 (2012).

    3. Hattermann, K., Picard, S., Borgeat, M., et al. The toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis. The FASEB Journal 21(7), 1575-1585 (2007).

    4. Bishop, G.A., Hsing, Y., Hostager, B.S., et al. Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J. Immunol. 165(10), 5552-5557 (2000).

    5. Caron, G., Duluc, D., Frémaux, I., et al. Direct stimulation of human T cells via TLR5 and TLR7/8: Flagellin and R-848 up-regulate proliferation and IFN-γ production by memory CD4+ T cells. J. Immunol. 175(3), 1551-1557 (2005).

    Product Citations

    Pauli, G., Chao, P.-H., Qin, Z., et al. Liposomal resiquimod for enhanced immunotherapy of peritoneal metastases of colorectal cancer. Pharmaceutics 13(10), 1696 (2021).